J. Witztum

发表

J. Witztum, 2009 .

Targeting APOC3 in the familial chylomicronemia syndrome.

D. Gaudet, D. Brisson, K. Tremblay, 2014, The New England journal of medicine.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.

B. Monia, S. Henry, T. Machemer, 2020, Nucleic acid therapeutics.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, S. Freedman, D. Blom, 2019, The New England journal of medicine.

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

D. Gaudet, R. Hegele, E. Steinhagen-Thiessen, 2021, The lancet. Diabetes & endocrinology.

The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study

J. Witztum, M. Davidson, A. Hsieh, 2017, Expert review of cardiovascular therapy.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

D. Gaudet, J. Kastelein, D. Brisson, 2015, The New England journal of medicine.

Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2’-MOE-Modified Antisense Oligonucleotide

J. Nolan, S. Henry, S. Burel, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.

A. Mertens, A. Garg, E. Hurh, 2022, Journal of clinical lipidology.

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.

J. E. Roeters van Lennep, J. Witztum, M. Davidson, 2018, Journal of clinical lipidology.

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

S. Crooke, S. Bhanot, Nelson Salgado, 2017, Nucleic acid therapeutics.

Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist

D. Gaudet, M. Malloy, E. Bruckert, 2016 .

Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial

D. Gaudet, E. Steinhagen-Thiessen, I. Gouni-Berthold, 2017, Atherosclerosis Supplements.

The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

D. Gaudet, Joann D Flaim, L. Hemphill, 2017, Atherosclerosis.

The foundations of the house (Q 2: 127)1

J. Witztum, 2009, Bulletin of the School of Oriental and African Studies.

Misplaced Verses: a Qurʾānic Hermeneutic of One Early Shiite Approach

J. Witztum, 2020 .

Joseph among the Ishmaelites: Q 12 in light of Syriac sources

J. Witztum, 2012 .

RNA-Targeted Therapeutics.

S. Crooke, J. Witztum, B. Baker, 2018, Cell metabolism.

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Richard G. Lee, E. Hurh, M. Graham, 2017, The New England journal of medicine.

Hyperkalemia during treatment with HMG-CoA reductase inhibitor.

J. Witztum, S. Edelman, 1989, The New England journal of medicine.

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

D. Gaudet, R. Hegele, E. Bruckert, 2019, Journal of the Endocrine Society.

Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS †

D. Gaudet, E. Bruckert, E. Stroes, 2018 .

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.

D. Gaudet, M. Arca, E. Stroes, 2023, Journal of clinical lipidology.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, M. Arca, S. Tsimikas, 2019, The New England journal of medicine.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

In Memoriam: Roger A. Davis (1945–2008)

P. Edwards, A. Attie, A. Lusis, 2008, Journal of Lipid Research.

Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. Reply.

J. Witztum, Louis O'Dea, Richard S. Geary, 2019, The New England journal of medicine.

APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.

S. Tsimikas, S. Xia, E. Karwatowska-Prokopczuk, 2023, Journal of clinical lipidology.

Familial Chylomicronemia Syndrome (FCS) Patients Recruited to the APPROACH Trial of Volanesorsen Therapy are Representative of Subjects with FCS

D. Gaudet, M. Malloy, J. Kane, 2017 .

1 Variant Traditions, Relative Chronology, and the Study of Intra-Quranic Parallels

J. Witztum, 2014 .

Ibn Ishaq and the Pentateuch in Arabic

J. Witztum, 2013 .